๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma

โœ Scribed by B. J. Lipworth; R. A. Clark; D. P. Dhillon; J. B. D. Palmer; D. G. McDevitt

Publisher
Springer
Year
1990
Tongue
English
Weight
576 KB
Volume
39
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Comparison of the efficacy, tolerability
Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma
โœ S. D. Gunn; J. G. Ayres; R. M. A. Follows; S. M. McConchie ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› Springer ๐ŸŒ English โš– 549 KB

The aim of the study was to compare the efficacy, tolerability and patient acceptability of bambuterol (Bambec ยฎ) against controlled release (CR) salbutamol (Volmax ยฎ) in the treatment of nocturnal asthma. One hundred and fifty two asthmatic patients aged 17-78 years, using \_> 800 ~tg/day of an in

Comparison of a 10-mg controlled release
Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients
โœ Carl Gustaf Nilsson; Eeva Lukkari; Mervi Haarala; Aarre Kivelรค; Tiina Hakonen; P ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 68 KB

Oxybutynin has long been used for the treatment of patients with detrusor overactivity and urinary urge incontinence. The short half-life of oxybutynin administered as a conventional tablet formulation or syrup requires 2-3 times daily dosage to be effective. A new controlled release (CR) tablet for

Efficacy and safety of the 200โ€“300 mg su
Efficacy and safety of the 200โ€“300 mg sustained release formulation of diltiazem administered once daily in patients with stable angina
โœ B. Trimarco; D. Radzik; E. Neveux; A. Wajman; P. Attali; W. Mieghem; J. Ponsonna ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› Springer ๐ŸŒ English โš– 371 KB

The aim of this multicentre randomised double blind study was to compare the efficacy and safety of the 200-300 mg sustained release diltiazem formulation administered once daily (200-300 SR) with standard diltiazem (D) given three or four times daily to patients with stable angina. Patients aged 59